Opioid Use Disorder Market Research Report Information By Drug Type (Buprenorphine, Naltrexone, Methadone), By Route of Administration (Intravenous, Oral), By Age Group (19 to 40, 41 to 60, 61 and Over), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. OPIOID USE DISORDER MARKET, BY DRUG TYPE

6.1. Overview

6.2. Buprenorphine

6.3. Naltrexone

6.4. Methadone

7. OPIOID USE DISORDER MARKET, BY AGE GROUP

7.1. Overview

7.2. 19 to 40

7.3. 41 to 60

7.4. 61 and over

8. OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION

8.1. Overview

8.2. Intravenous

8.3. Oral

9. OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL

9.1. Overview

9.2. Hospital pharmacies

9.3. Retail pharmacies

9.4. Online pharmacies

10. OPIOID USE DISORDER MARKET, BY REGION

10.1. Overview

10.1. North America

10.1.1. US

10.1.2. Canada

10.2. Europe

10.2.1. Germany

10.2.2. France

10.2.3. UK

10.2.4. Italy

10.2.5. Spain

10.2.6. Rest of Europe

10.3. Asia-Pacific

10.3.1. China

10.3.2. India

10.3.3. Japan

10.3.4. South Korea

10.3.5. Australia

10.3.6. Rest of Asia-Pacific

10.4. Rest of the World

10.4.1. Middle East

10.4.2. Africa

10.4.3. Latin America

11. COMPETITIVE LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Opioid use disorder Market,

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Opioid use disorder Market,

11.7. Key developments and Growth Strategies

11.7.1. New Product Launch/Service Deployment

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2022

11.8.2. Major Players R&D Expenditure. 2022

12. COMPANY PROFILES

12.1. Alkermes, Inc.

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Products Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Indivior PLC

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Products Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. BioDelivery Sciences International, Inc.

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Products Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Orexo US, Inc.

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Products Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Titan Pharmaceuticals, Inc.

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Products Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Omeros Corporation

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Products Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Camurus

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Products Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. HIKMA PHARMACEUTICALS PLC

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Products Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. AstraZeneca plc

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Products Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Viatris Inc.

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Products Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 OPIOID USE DISORDER MARKET, SYNOPSIS, 2018-2032

TABLE 2 OPIOID USE DISORDER MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 4 OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 5 OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 6 OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 9 NORTH AMERICA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 10 NORTH AMERICA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 11 US: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 12 US: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 13 US: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 14 US: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 15 CANADA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 16 CANADA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 17 CANADA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 18 CANADA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 2 EUROPE: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 3 EUROPE: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 4 EUROPE: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 5 GERMANY: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 6 GERMANY: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 7 GERMANY: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 8 GERMANY: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 9 FRANCE: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 10 FRANCE: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 11 FRANCE: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 12 FRANCE: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 13 ITALY: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 14 ITALY: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 15 ITALY: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 16 ITALY: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 17 SPAIN: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 18 SPAIN: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 19 SPAIN: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 20 SPAIN: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 21 UK: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 22 UK: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 23 UK: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 24 UK: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 25 REST OF EUROPE: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 26 REST OF EUROPE: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 27 REST OF EUROPE: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 28 REST OF EUROPE: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 29 ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 30 ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 31 ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 32 ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 33 JAPAN: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 34 JAPAN: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 35 JAPAN: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 36 JAPAN: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 37 CHINA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 38 CHINA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 39 CHINA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 40 CHINA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 41 INDIA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 42 INDIA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 43 INDIA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 44 INDIA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 45 AUSTRALIA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 46 AUSTRALIA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 47 AUSTRALIA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 48 AUSTRALIA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 49 SOUTH KOREA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 50 SOUTH KOREA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 51 SOUTH KOREA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 52 SOUTH KOREA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 53 REST OF ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 54 REST OF ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 55 REST OF ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 56 REST OF ASIA-PACIFIC: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 57 REST OF THE WORLD: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 58 REST OF THE WORLD: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 59 REST OF THE WORLD: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 60 REST OF THE WORLD: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 61 MIDDLE EAST: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 62 MIDDLE EAST: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 63 MIDDLE EAST: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 64 MIDDLE EAST: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 65 AFRICA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 66 AFRICA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 67 AFRICA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 68 AFRICA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 69 LATIN AMERICA: OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 70 LATIN AMERICA: OPIOID USE DISORDER MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)

TABLE 71 LATIN AMERICA: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)

TABLE 72 LATIN AMERICA: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE OPIOID USE DISORDER MARKET

FIGURE 3 MARKET DYNAMICS FOR THE OPIOID USE DISORDER MARKET

FIGURE 4 OPIOID USE DISORDER MARKET, SHARE (%), BY DRUG TYPE, 2022

FIGURE 5 OPIOID USE DISORDER MARKET, SHARE (%), BY AGE GROUP, 2022

FIGURE 6 OPIOID USE DISORDER MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2022

FIGURE 7 OPIOID USE DISORDER MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022

FIGURE 8 OPIOID USE DISORDER MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 NORTH AMERICA: OPIOID USE DISORDER MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 EUROPE: OPIOID USE DISORDER MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 ASIA-PACIFIC: OPIOID USE DISORDER MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 REST OF THE WORLD: OPIOID USE DISORDER MARKET, SHARE (%), BY REGION, 2022

FIGURE 13 OPIOID USE DISORDER MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 14 ALKERMES, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 ALKERMES, INC.: SWOT ANALYSIS

FIGURE 16 INDIVIOR PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 INDIVIOR PLC: SWOT ANALYSIS

FIGURE 18 BIODELIVERY SCIENCES INTERNATIONAL, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 BIODELIVERY SCIENCES INTERNATIONAL, INC.: SWOT ANALYSIS

FIGURE 20 OREXO US, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 OREXO US, INC.: SWOT ANALYSIS

FIGURE 22 TITAN PHARMACEUTICALS, INC..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 TITAN PHARMACEUTICALS, INC..: SWOT ANALYSIS

FIGURE 24 OMEROS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 OMEROS CORPORATION: SWOT ANALYSIS

FIGURE 26 CAMURUS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 CAMURUS: SWOT ANALYSIS

FIGURE 28 HIKMA PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 HIKMA PHARMACEUTICALS PLC: SWOT ANALYSIS

FIGURE 30 ASTRAZENECA PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 ASTRAZENECA PLC: SWOT ANALYSIS

FIGURE 32 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 VIATRIS INC.: SWOT ANALYSIS